1095 related articles for article (PubMed ID: 8492764)
21. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
Postema EJ; Börjesson PK; Buijs WC; Roos JC; Marres HA; Boerman OC; de Bree R; Lang M; Munzert G; van Dongen GA; Oyen WJ
J Nucl Med; 2003 Oct; 44(10):1690-9. PubMed ID: 14530488
[TBL] [Abstract][Full Text] [Related]
22. Comparison of systemic radiotherapy with I-131-labeled monoclonal antibody BW575/9 to external beam radiotherapy in human neuroblastoma xenografts.
Sautter-Bihl ML; Wessely R; Bihl H
Strahlenther Onkol; 1993 Oct; 169(10):595-600. PubMed ID: 8235984
[TBL] [Abstract][Full Text] [Related]
23. Two-step targeting of xenografted colon carcinoma using a bispecific antibody and 188Re-labeled bivalent hapten: biodistribution and dosimetry studies.
Gestin JF; Loussouarn A; Bardiès M; Gautherot E; Gruaz-Guyon A; Saï-Maurel C; Barbet J; Curtet C; Chatal JF; Faivre-Chauvet A
J Nucl Med; 2001 Jan; 42(1):146-53. PubMed ID: 11197965
[TBL] [Abstract][Full Text] [Related]
24. Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments.
Casey JL; Pedley RB; King DJ; Green AJ; Yarranton GT; Begent RH
Br J Cancer; 1999 Nov; 81(6):972-80. PubMed ID: 10576653
[TBL] [Abstract][Full Text] [Related]
25. Application of the cross-organ beta dose method for tissue dosimetry in tumor-bearing mice treated with a 90Y-labeled immunoconjugate.
Beatty BG; Kuhn JA; Hui TE; Fisher DR; Williams LE; Beatty JD
Cancer; 1994 Feb; 73(3 Suppl):958-65. PubMed ID: 8306285
[TBL] [Abstract][Full Text] [Related]
26. Carcinoembryonic antigen as a target for radioimmunotherapy of human medullary thyroid carcinoma: antibody processing, targeting, and experimental therapy with 131I and 90Y labeled MAbs.
Stein R; Juweid M; Mattes MJ; Goldenberg DM
Cancer Biother Radiopharm; 1999 Feb; 14(1):37-47. PubMed ID: 10850286
[TBL] [Abstract][Full Text] [Related]
27. Dosimetry of intraperitoneally administered radiolabeled antibodies.
Roeske JC; Chen GT; Brill AB
Med Phys; 1993; 20(2 Pt 2):593-600. PubMed ID: 8492768
[TBL] [Abstract][Full Text] [Related]
28. Multicellular dosimetry for beta-emitting radionuclides: autoradiography, thermoluminescent dosimetry and three-dimensional dose calculations.
Yorke ED; Williams LE; Demidecki AJ; Heidorn DB; Roberson PL; Wessels BW
Med Phys; 1993; 20(2 Pt 2):543-50. PubMed ID: 8492763
[TBL] [Abstract][Full Text] [Related]
29. Radiobiology of radiolabeled antibody therapy as applied to tumor dosimetry.
Langmuir VK; Fowler JF; Knox SJ; Wessels BW; Sutherland RM; Wong JY
Med Phys; 1993; 20(2 Pt 2):601-10. PubMed ID: 8492769
[TBL] [Abstract][Full Text] [Related]
30. Intratumoral distribution of radiolabeled antibody and radioimmunotherapy in experimental liver metastases model of nude mouse.
Sato N; Saga T; Sakahara H; Yao Z; Nakamoto Y; Zhang M; Kuroki M; Matsuoka Y; Iida Y; Konishi J
J Nucl Med; 1999 Apr; 40(4):685-92. PubMed ID: 10210230
[TBL] [Abstract][Full Text] [Related]
31. Tumor retention of 186Re-MAG3, 111In-DTPA and 125I labeled monoclonal antibody G250 in nude mice with renal cell carcinoma xenografts.
Steffens MG; Kranenborg MH; Boerman OC; Zegwaart-Hagemeier NE; Debruyne FM; Corstens FH; Oosterwijk E
Cancer Biother Radiopharm; 1998 Apr; 13(2):133-9. PubMed ID: 10850349
[TBL] [Abstract][Full Text] [Related]
32. Comparisons of sectioned micro-TLD dose measurements with predicted dose from 131I-labeled antibody.
Langmuir VK; Wessels BW; Mendonca H; Yorke ED; Montilla L
Med Phys; 1992; 19(5):1213-6. PubMed ID: 1435601
[TBL] [Abstract][Full Text] [Related]
33. Targeted therapy of athymic mice bearing GW-39 human colonic cancer micrometastases with 131I-labeled monoclonal antibodies.
Blumenthal RD; Sharkey RM; Haywood L; Natale AM; Wong GY; Siegel JA; Kennel SJ; Goldenberg DM
Cancer Res; 1992 Nov; 52(21):6036-44. PubMed ID: 1394228
[TBL] [Abstract][Full Text] [Related]
34. The nonuniformity of antibody distribution in the kidney and its influence on dosimetry.
Flynn AA; Pedley RB; Green AJ; Dearling JL; El-Emir E; Boxer GM; Boden R; Begent RH
Radiat Res; 2003 Feb; 159(2):182-9. PubMed ID: 12537523
[TBL] [Abstract][Full Text] [Related]
35. Radioimmunotherapy with radioactive nanoparticles: first results of dosimetry for vascularized and necrosed solid tumors.
Bouchat V; Nuttens VE; Lucas S; Michiels C; Masereel B; Féron O; Gallez B; Vander Borght T
Med Phys; 2007 Nov; 34(11):4504-13. PubMed ID: 18072516
[TBL] [Abstract][Full Text] [Related]
36. 211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo.
Bäck T; Andersson H; Divgi CR; Hultborn R; Jensen H; Lindegren S; Palm S; Jacobsson L
J Nucl Med; 2005 Dec; 46(12):2061-7. PubMed ID: 16330571
[TBL] [Abstract][Full Text] [Related]
37. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
[TBL] [Abstract][Full Text] [Related]
38. 131I radioimmunotherapy and fractionated external beam radiotherapy: comparative effectiveness in a human tumor xenograft.
Barendswaard EC; O'Donoghue JA; Larson SM; Tschmelitsch J; Welt S; Finn RD; Humm JL
J Nucl Med; 1999 Oct; 40(10):1764-8. PubMed ID: 10520720
[TBL] [Abstract][Full Text] [Related]
39. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
Tijink BM; Neri D; Leemans CR; Budde M; Dinkelborg LM; Stigter-van Walsum M; Zardi L; van Dongen GA
J Nucl Med; 2006 Jul; 47(7):1127-35. PubMed ID: 16818947
[TBL] [Abstract][Full Text] [Related]
40. 186Re-labeled monoclonal antibody E48 immunoglobulin G-mediated therapy of human head and neck squamous cell carcinoma xenografts.
Gerretsen M; Visser GW; van Walsum M; Meijer CJ; Snow GB; van Dongen GA
Cancer Res; 1993 Aug; 53(15):3524-9. PubMed ID: 8339258
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
